OJOG> Vol.2 No.3, September 2012

The diagnostic accuracy of the usage of the Fetal Medicine Foundation’s (FMF) on-line risk calculator with first-trimester ultrasound for screening for preeclampsia in high-risk pregnant Brazilian population

DownloadDownload as PDF (Size:84KB)  HTML    PP. 298-303  

ABSTRACT

To evaluate the sensitivity and specificity of the usage of the FMF On-Line Risk Calculator with first-trimester ultrasound, in screening assessment for preeclampsia (PE), without serum markers. To define the best risk cut-off values for early, intermediate and late preeclampsia. Diagnostic accuracy study of pregnant women who had first-trimester ultrasounds between 11 and 13 weeks. The index test was the first-trimester ultrasound scan plus the FMF On-Line Risk Calculator to assess the risk for PE. The reference standard was the confirmation of actual development of early, intermediate or late PE. For calculations of sensitivity and specificity to determine the best cut-off values for early, intermediate and late PE, all the information was processed into ROC curves. The assessment of preeclampsia risk in the first trimester using an ultrasound plus the FMF On-Line Risk Calculator demonstrated a significant (p < 0.05) area under the ROC curve for early, intermediate and late preeclampsia. The best risk cut-off values were defined as 2.1% for early, 2.5% for intermediate and 3.5% for late preeclampsia. The first trimester US plus the FMF On-Line Risk Calculator tool was useful and applicable when assessing the risk for preeclampsia in a specific pregnant Brazilian population.

Cite this paper

Figueiró-Filho, E. , Galhardo, M. and de Souza, B. (2012) The diagnostic accuracy of the usage of the Fetal Medicine Foundation’s (FMF) on-line risk calculator with first-trimester ultrasound for screening for preeclampsia in high-risk pregnant Brazilian population. Open Journal of Obstetrics and Gynecology, 2, 298-303. doi: 10.4236/ojog.2012.23063.

References

[1] Ismail, S.K. and Higgins, J.R. (2011) Hemostasis in pre-eclampsia. Seminars in Thrombosis and Hemostasis, 37, 111-117. doi:10.1055/s-0030-1270336
[2] Steegers, E.A., von Dadelszen, P., Duvekot, J.J. and Pijnenborg, R. (2010) Pre-eclampsia. Lancet, 376, 631-644. doi:10.1016/S0140-6736(10)60279-6
[3] World Health Organization Department of Reproductive Health and Research, Department of Maternal, Newborn, Child and Adolescent Health, Department of Nutrition for Health and Development (2011) WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneve.
[4] Akolekar, R., Syngelaki, A., Sarquis, R., Zvanca, M. and Nicolaides, K.H. (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11 - 13 weeks. Prenatal Diagnosis, 31, 66-74. doi:10.1002/pd.2660
[5] Kahn, S.R., Platt, R., McNamara, H., Rozen, R., Chen, M.F., Genest, J., et al. (2009) Inherited thrombophilia and pre-eclampsia within a multicenter cohort: The Montreal pre-eclampsia study. American Journal of Obstetrics and Gynecology, 200, 151.e1-151.e9.
[6] Cantwell, R., Clutton-Brock, T., Cooper, G., Dawson, A., Drife, J., Garrod, D., et al. (2011) Saving mothers’ lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. BJOG: An International Journal of Obstetrics & Gynaecology, 118, 1-203.
[7] Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., et al. (2010) Prevention of pre-eclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstetrics & Gynecology, 116, 402-414. doi:10.1097/AOG.0b013e3181e9322a
[8] Roberge, S., Villa, P., Nicolaides, K., Giguère, Y., Vainio, M., Bakthi, A., et al. (2012) Early administration of low-dose aspirin for the prevention of preterm and term pre-eclampsia: A systematic review and meta-analysis. Fetal Diagnosis and Therapy, 31, 141-146. doi:10.1159/000336662
[9] Nanda, S., Akolekar, R., Sarquis, R., Mosconi, A.P. and Nicolaides, K.H. (2011) Maternal serum adiponectin at 11 to 13 weeks of gestation in the prediction of macrosomia. Prenatal Diagnosis, 31, 479-483. doi:10.1002/pd.2723
[10] Nanda, S., Savvidou, M., Syngelaki, A., Akolekar, R. and Nicolaides, K.H. (2011) Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenatal Diagnosis, 31, 135-141. doi:10.1002/pd.2636
[11] Beta, J., Akolekar, R., Ventura, W., Syngelaki, A. and Nicolaides, K.H. (2011) Prediction of spontaneous pre-term delivery from maternal factors, obstetric history and placental perfusion and function at 11 - 13 weeks. Prenatal Diagnosis, 31, 75-83. doi:10.1002/pd.2662
[12] Karagiannis, G., Akolekar, R., Sarquis, R., Wright, D. and Nicolaides, K.H. (2011) Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11 - 13 weeks. Fetal Diagnosis and Therapy, 29, 148-154. doi:10.1159/000321694
[13] Poon, L.C., Kametas, N.A., Maiz, N., Akolekar, R. and Nicolaides, K.H. (2009) First-trimester prediction of hypertensive disorders in pregnancy. Hypertension, 53, 812-818. doi:10.1161/HYPERTENSIONAHA.108.127977
[14] Nicolaides, K.H. (2011) Screening for fetal aneuploidies at 11 to 13 weeks. Prenatal Diagnosis, 31, 7-15. doi:10.1002/pd.2637
[15] Nicolaides, K.H. (2011) A model for a new pyramid of prenatal care based on the 11 to 13 weeks’ assessment. Prenatal Diagnosis, 31, 3-6. doi:10.1002/pd.2685
[16] Plasencia, W., Maiz, N., Poon, L., Yu, C. and Nicolaides, K.H. (2008) Uterine artery doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound in Obstetrics & Gynecology, 32, 138-146. doi:10.1002/uog.5402
[17] Poon, L.C., Staboulidou, I., Maiz, N., Plasencia, W. and Nicolaides, K.H. (2009) Hypertensive disorders in pregnancy: Screening by uterine artery doppler at 11 - 13 weeks. Ultrasound in Obstetrics & Gynecology, 34, 142-148. doi:10.1002/uog.6452
[18] Poon, L.C., Karagiannis, G., Leal, A., Romero, X.C. and Nicolaides, K.H. (2009) Hypertensive disorders in pregnancy: Screening by uterine artery doppler imaging and blood pressure at 11 - 13 weeks. Ultrasound in Obstetrics & Gynecology, 34, 497-502. doi:10.1002/uog.7439
[19] Poon, L.C., Stratieva, V., Piras, S., Piri, S. and Nicolaides, K.H. (2010) Hypertensive disorders in pregnancy: Combined screening by uterine artery doppler, blood pressure and serum PAPP-A at 11 - 13 weeks. Prenatal Diagnosis, 30, 216-223.
[20] Poon, L.C., Kametas, N.A., Chelemen, T., Leal, A. and Nicolaides, K.H. (2010) Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. Journal of Human Hypertension, 24, 104-110. doi:10.1038/jhh.2009.45
[21] Poon, L.C., Kametas, N.A., Valencia, C., Chelemen, T. and Nicolaides, K.H. (2011) Hypertensive disorders in pregnancy: Screening by systolic diastolic and mean arterial pressure at 11 - 13 weeks. Hypertension in Pregnancy, 30, 93-107. doi:10.3109/10641955.2010.484086
[22] Poon, L.C., Zymeri, N.A., Zamprakou, A., Syngelaki, A. and Nicolaides, K.H. (2012) Protocol for measurement of mean arterial pressure at 11 - 13 weeks’ gestation. Fetal Diagnosis and Therapy, 31, 42-48. doi:10.1159/000335366
[23] Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L.M., et al. (2003) The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Croatian Medical Journal, 44, 639-650.
[24] Akolekar, R., Etchegaray, A., Zhou, Y., Maiz, N. and Nicolaides, K.H. (2009) Maternal serum activin a at 11 - 13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagnosis and Therapy, 25, 320-327. doi:10.1159/000235878
[25] Van der Schouw, Y.T., Van Dijk, R. and Verbeek, A.L. (1995) Problems in selecting the adequate patient population from existing data files for assessment studies of new diagnostic tests. Journal of Clinical Epidemiology, 48, 417-422. doi:10.1016/0895-4356(94)00144-F

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.